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Background. Haptoglobin acts as an antioxidant by limiting peroxidative tissue damage by free hemoglobin. The haptoglobin
gene allele Hp2 comprises a 1.7 kb partial duplication. Relative to allele Hp1, Hp2 carriers form protein multimers, suboptimal for
hemoglobin scavenging.Objective. To examine the association of haptoglobin genotype with a range of phenotypes, with emphasis
on vitamin C and hemoglobin levels.Methods. We applied a quantitative PCR assay for the duplication junction to two population
cohorts including 2747 British women and 1198 British men. We examined the association of haptoglobin duplicon copy number
with hemoglobin and vitamin C and used the copy number to complete a phenome scan. Results. Hemoglobin concentrations
were greater in those with Hp2,2 genotype, in women only (Hp1,1 13.45 g/dL, Hp1,2 13.49 g/dL, Hp2,2 13.61 g/dL; 𝑃 = 0.002),
though statistically there was no evidence of a difference between the sexes (𝑧 value = 1.2, 𝑃 = 0.24). Haptoglobin genotype was
not associated with vitamin C or any other phenotype in either cohort. Conclusions. Our results do not support association of
haptoglobin genotype with vitamin C or with other phenotypes measured in two population cohorts. The apparent association
between haptoglobin genotype and hemoglobin in the women’s cohort merits further investigation.
1. Introduction
The haptoglobin gene HP exists in the human population in
two forms: Hp1 and Hp2 (throughout this paper the classic
haptoglobin duplicon nomenclature will be used, i.e., Hp1
refers to the allele without the duplication and Hp2 refers
to the allele with duplication). Hp1 is the less frequent allele
in Europeans. Hp1,1 refers to the homozygote for the Hp1
allele, and Hp2,2 refers to the homozygote for the Hp2 allele.
Exons 5 and 6 ofHp2 represent duplication of a 1.7 kb segment
containing exons 3 and 4 of Hp1 [1]. The protein product for
Hp1,1 forms a dimer, whereas the products of Hp1,2 or Hp2,2
are multimers of varying size and complexity, greater in the
Hp2,2 genotype. The principal function of haptoglobin,
which is normally present at a greater than 400-fold molar
excess compared with free hemoglobin [2], is to scavenge free
hemoglobin [3] which has been liberated into the plasma by
intravascular haemolysis.The haptoglobin/hemoglobin com-
plex is cleared from the bloodstream by circulating mono-
cytes or in the liver by Kuppfer cells, and the heme iron is
recycled. At sites of tissue damage, the complex is cleared by
macrophages.
The range of possible forms of haptoglobin, from dimer
to large multimer depending on genotype, results in a gene
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product with a range of properties and potentially complex
interactions. For example, although the hemoglobin-binding
capacity of Hp2,2 is lower than that of Hp1,1 [4], the Hp2,2-
hemoglobin complex binds to CD163 (the haptoglobin recep-
tor expressed on macrophage and monocyte cell surfaces)
with a 10-fold higher affinity than the Hp1,1-hemoglobin
complex [5].
The aim of this study was to examine the association
of haptoglobin genotype with a wide range of phenotypes.
This is justified on the basis of the hypothesised antioxidant
properties of haptoglobin and claims for the involvement of
antioxidation in a wide range of health related outcomes.
However, within this broad phenome scan, we had three
specific prior hypotheses.
(1) Higher levels of vitamin Cwould be found in individ-
uals not carrying the Hp2 allele because haptoglobin
is involved in redox reaction, which should affect
vitamin C levels [6] and, as described above, is inti-
mately involved with the scavenging of circulating
hemoglobin.
(2) Higher total levels of hemoglobin would be found
in individuals carrying the Hp2 allele because of less
efficient clearance. This hypothesis was based on the
specific high affinity protein interaction of hap-
toglobin with hemoglobin and reports of haptoglo-
bin genotype association with hemoglobin level in
malaria [7].
2. Materials and Methods
We developed a novel high-throughput liquid-phase assay
for detection of the Hp duplicon, based on fluorescence
ratiometry between junction and reference polymerase chain
reaction (PCR) amplicons using a melt curve analysis [8].
We used this assay to genotype participants in two British
cohort studies: the British Women’s Heart and Health Study
(BWHHS) and the Caerphilly Prospective Study (CaPS) of
men. Because of the possibility that copy number variation
inHp could have a wide range of effects, relating to its antiox-
idant properties, we completed a “phenome scan” in these two
cohorts, examining a range of blood measures and clinical
traits with genotype.
2.1. British Women’s Heart and Health Study (BWHHS).
BWHHS is a cohort of 4,286 women, who were randomly
selected from 23 British towns and who were of the age
between 60 and 79 years at enrolment (1999–2001) [9]. At
baseline assessment the women completed a questionnaire,
a nurse-led health interview, and a physical examination at
which fasting blood samples (minimum 8 hours) were taken.
Medical records were reviewed for all evidence of past history
of cardiovascular disease, type 2 diabetes, and cancer. The
women have been followed up with information on new
disease events obtained from participant completed ques-
tionnaires and a two-year review of their medical records and
with mortality data obtained from the UK National Health
Service central register.
For further details of BWHHS, including analyte prepa-
ration, please see Supplementary Material available online at
http://dx.doi.org/10.1155/2014/529456.
2.2. Caerphilly Prospective Study (CaPS). All men fromCaer-
philly, South Wales, and surrounding villages of age between
45 and 59 years were contacted and invited to take part in
a health survey, resulting in 2512 (89% response rate) men
participating in the baseline examination that was under-
taken between 1979 and 1983 (Phase I). Phase II (1984–1988)
consisted of those from Phase I who had been recontacted,
together with an additional group who had since moved
into the study area (Phase II 𝑛 = 2,398). The examination
consisted of a standard medical history, venepuncture for
biochemical and hormonal assays, and physical examination
including weight, height, blood pressure, and 12-lead ECG.
Hemoglobin was measured by a modification of the Dacie
and Lewis method using a dedicated hemoglobinometer.
VitaminCwas notmeasured. Subjects were defined as having
diabetes (type 2 unless otherwise specified) if they had been
previously diagnosed by their general practitioner or if their
fasting glucose concentrations were greater than or equal
to 7.8mmoL/L. Other phenome variables were measured as
described previously [10]. Of the participants for whomDNA
was available, 1198 had complete data on the combination of
CHD, type 2 diabetes (based on self-reported diagnosis from
questionnaires), and haptoglobin genotype, and so all our
analyses were conducted on 1198 men.
2.2.1. Genotyping Assay. The Hp junction region and a refer-
ence sequence in TP53 not subject to copy number variation
were coamplified by PCR. Reactions were performed using
20 ng genomic DNA as template in 384-well plates. Following
33-cycle PCR optimised to preserve ratio of amplification of
test and reference, the ratio of test to reference was deter-
mined by fluorescence quantification of Eva Green binding
during real timemelting of the amplicons in a 384-well Light-
Typer (RocheDiagnostics); test and reference ampliconswere
designed to melt at different temperatures [8]. Validations
included typing of genotype knownDNAs (gift of Dr.Werner
Koch (German Heart Centre, Lazarettstrasse 36, D-80636,
Munich) and Dr. Joris Delanghe (Department of Laboratory
Medicine, UniversityHospital Ghent, Belgium)), comparison
of our ratiometric assaywith the assay described byKoch et al.
[11], and evaluation of the cluster quality differentiating the
clusters of ratios representing 1 or 2 copies of theHP duplicon
junction. The absence of a target amplicon first derivative
fluorescence peak but presence of a reference peak signified
zero copies of the duplicon junction.
3. Statistics
Linear (for continuous traits) and logistic (for binary traits)
regression was used to examine the association of geno-
type with phenotypes. Where traits were positively skewed
(triglycerides, glucose, insulin), we used a natural logarithm
transformation in these regression analyses and then back-
transformed for table presentation.The 𝑃 value, with Bonfer-
roni correction, for the phenome scan of the BWHHS data
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Table 1: Haptoglobin genotype and allele frequency for BWHHS
and CaPS cohorts.
Genotype/Allele Number (%) [expected number]
BWHHS CaPS
Hp1,1 417 (13.3) [416.2] 204 (14.4) [210.9]
Hp1,2 1447 (46.3) [1448.5] 685 (48.4) [671.2]
Hp2,2 1261 (40.3) [1260.2] 527 (37.2) [533.9]
Hp1 2281 (36.5) 1093 (38.6)
Hp2 3969 (63.5) 1739 (61.4)
BWHHS CaPS
HWE chi2, 1df (𝑃) 0.0 (1.00) 0.6 (0.44)
Test for difference in allele frequencies between the two cohorts (Chi-square
= 3.52, 𝑃 = 0.06) (N.B. totals for those with valid HP CNV genotype data but
not necessarily overlapping other phenotypes).
was set at (0.05/31 = 0.0016) and of the CaPS data was set at
(0.05/24 = 0.0021).
4. Results
Table 1 summarises genotype and allele frequency data for the
two cohorts.
Genotype and allele frequencies were similar in the two
studies.
Table 2 shows the results of tests for association bet-
ween haptoglobin genotype and vitamin C concentration,
hemoglobin level, and CHD, for BWHHS and CaPS (from
phase 2). Haptoglobin genotype is associated with hemoglo-
bin level in BWHHS (hemoglobin concentration increasing
with number of Hp2 alleles) but not with CHD or vitamin
C concentration. Haptoglobin genotype was not associated
with coronary disease or hemoglobin concentration in CaPS.
Though an association with haemoglobin was observed in
BWHHS and not in CaPS, there was no statistical evidence
that the association differed between these two studies (𝑃
value from 𝑧-test = 0.24).
5. Validation Results
Table 3 compares HP duplicon genotyping results using the
assay of Koch et al. [11] and using our ratiometric assay
(amplification ratio control system—ARCS). Genotypingwas
fully concordant between the two methods apart from Hp1,2
(96% concordance).
The stated HP CNV genotypes of the control samples
provided by Dr. Werner Koch and Kr. Joris Delanghe were
in full agreement with those determined by ARCS (data not
shown).
Figure 5 in [8] shows anARCS plot of reference gene peak
height on the 𝑥-axis againstHP gene CNV peak height on the
𝑦-axis, for 85 samples. Hp1,1 Hp1,2, and Hp2,2 are seen to be
separated into three distinct clusters radiating from the
origin, providing good discrimination among the three geno-
types.
Supplementary Data Tables 1 and 2 show the associa-
tions of haptoglobin genotype with phenome scan traits in
BWHHS and in CaPS, respectively. Haptoglobin genotype
was not associated with any phenotypes in either cohort,
except for the association with hemoglobin in BWHHS as
discussed above.
SupplementaryData Table 3 shows the haptoglobin geno-
type and allele frequencies by quartile of vitamin C distri-
bution in BWHHS. No associations between genotype/allele
frequency and vitamin C distribution were found.
6. Discussion
We examined the association between haptoglobin genotype
and clinical traits in two British cohorts, with prior hypothe-
ses for association with diabetic CHD, hemoglobin, and
vitamin C level. Evidence of association with CHD, diabetic
CHD, or vitamin C was lacking. Though haptoglobin geno-
type did show nominal associationwith hemoglobin, this was
only in BWHHS and was not replicated in CaPS, though
statistically the association was consistent between the two
studies. Furthermore, despite the hypothesised antioxidant
properties of haptoglobin and claims for the involvement of
antioxidation in a wide range of health related outcomes, we
found no compelling evidence that haptoglobin genotypewas
associated with a large number of phenotypes examined in
our phenome scans (Supplementary Tables 1 and 2).
6.1. Haptoglobin Genotype and Vitamin C Status. We did not
observe an association of haptoglobin genotype with plasma
vitamin C concentrations. A small study of Chinese males
(𝑁 = 50) [12] reported that individuals with Hp2,2-genotype
had lower (by 31%) vitamin C concentrations than those with
other genotypes (𝑃 < 0.01) but stated that there was no such
association in females (𝑁 = 60). It has also been reported [13]
that overall haptoglobin concentrations are lower in males
than females, resulting in lower stability of vitamin C in
males. Additionally, Langlois et al. [6] noted that, in partici-
pants consuming a vitamin C-poor diet, those with the Hp2,2
genotype were most likely to develop vitamin C deficiency.
Similarly, Cahill and El-Sohemy found that Hp2,2 partici-
pants had lower vitamin C concentrations when reported
dietary vitamin C was low, but not when it met the recom-
mended daily allowance [14].These reports, together with the
observations of Ness et al. [15] who showed a mean plasma
vitamin C level in European British females of approximately
1.35 times the level found inmales, suggest that our results for
the entirely female BWHHS cohort may be a reflection of the
vitamin C replete status of a large fraction of the participants
[16]. When our data were divided into quartiles by vitamin
C level (Supplementary Data Table 3) to test the hypothesis
that genotype effect might only be apparent in low vitamin C
quartiles, we also found no association.
6.2. Haptoglobin Genotype and Hemoglobin Levels. Our
data suggest an association of haptoglobin genotype with
hemoglobin level in BWHHS but not in CaPS.The difference
in the sexes of the two cohorts may partially account for this
result, since in several studies, hemoglobin concentrationwas
found to be higher in males compared with females [17–19],
but we found no statistical evidence that results did differ
between the two cohorts. Alternatively, the lack of association
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Table 2: Association of HP CNV genotype with vitamin C and hemoglobin for BWHHS and CaPS cohorts.
Means (SD) or𝑁 (%) of traits by genotype 𝑃 trend
Hp1,1 Hp1,2 Hp2,2 (1df)
Continuous outcomes: means (SD)
BWHHS Vitamin C (𝜇mol/L) 43.53 (27.47) 44.03 (28.75) 42.91 (28.26) 0.51
CaPS Vitamin C N/A N/A N/A N/A
BWHHS Hb (g/dL) 13.45 (1.00) 13.49 (1.14) 13.61 (1.00) 0.002
CaPS Hb (g/dL) 14.87 (1.35) 14.94 (1.05) 14.91 (1.03) 0.818
Hb: hemoglobin.
Table 3: Comparison ofHP duplicon genotyping results using Koch
assay and using Amplification Ratio Control System (ARCS) assay
for 64 data points.
Hp CNV genotype
Hp1,1 Hp1,2 Hp2,2 Fail
Koch assay (𝑛) 9 25 27 3
ARCS assay (𝑛) 9 24 27 4
between haptoglobin genotype and hemoglobin concentra-
tion in the CaPS cohort may be a type-2 error. Prior bio-
logical knowledge of the high affinity specific interaction
of haptoglobin with free hemoglobin (its main role) [20],
together with a publication showing an association of the
severity of anemia with haptoglobin genotype in patients
infected with malaria [21] and on reporting an association of
free hemoglobin level with haptoglobin genotype [12], led us
to hypothesise thatHP would be associated with hemoglobin
in the direction that we observed. Given the complex network
of regulation and interactions, direction of effect is difficult to
predict.We observe higher hemoglobin in theHp2,2 group in
BWHHS, contrasting with studies in malaria-endemic areas
where Hp2,2 (additively) associates with lower hemoglobin
levels in children during themalaria season and healthyHp1,1
subjects display approximately 50% higher free hemoglobin
levels in their plasma [12, 21].
Sex differences of iron turnover, as exemplified by protec-
tion of HFE gene homozygous mutant females from clinical
hemochromatosis [22], the higher serum iron concentration
found in Hp2,2 men but not Hp2,2 women, and the higher
vitamin C concentration found in women [23] may all be
important factors influencing effects of haptoglobin geno-
type.
In summary, our studies found no association between
haptoglobin genotype and vitamin C status. An association
was found between haptoglobin genotype and hemoglobin
concentration in the BWHHS cohort (older women), but
not in CaPS (middle-aged men). However, given the large
number of associations examined here and some evidence of
inconsistency of direction of association ofHPwith hemoglo-
bin in the literature, further replication of this finding is
required before we can claim that this association is robust. A
wider systems approach will be necessary to simultaneously
resolve effects in relation to sex, redox status, free hemoglobin
level, total hemoglobin level, and oxygen carriage, with
potentially more major effects in the presence of large
challenges to homeostasis such as those of malaria, diabetes,
or other diseases.
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